Abstract
BackgroundLeading to more and more deaths and disabilities, stroke has become a serious threat to human health. What’s more, few effective drugs are available in clinic till now.ResultsIn this research, we prepared a novel neuroprotective nanoformation (OEA–SPC NPs) via the combination of the nanoparticle drug delivery system with the endogenous N-oleoylethanolamine (OEA). By forming hydrogen bond between OEA and the carrier—soybean phosphatidylcholine (SPC), the form of OEA was turned into amorphus state when loading to the nanoparticles, which greatly improved its bioavailability. Then the following systematic experiments revealed the efficient neuroprotective effect of OEA–SPC NPs in vivo. Compared with the MCAO group, the cerebral infarct volume was reduced by 81.1%, and the edema degree by 78.4% via the oral administration of OEA–SPC NPs. And the neurological deficit scores illustrated that the MCAO rats treated with OEA–SPC NPs exhibited significantly less neurological dysfunction. The Morris water maze test indicated that the spatial learning and memory of cerebral ischemia model rats were almost recovered to the normal level. Besides, the OEA–SPC NPs could inhibit the inflammation of reperfusion to a very slight level.ConclusionsThese results suggest that the OEA–SPC NPs have a great chance to be a potential anti-stroke formation for clinic application and actually bring hope to thousands of stroke patients.
Highlights
Leading to more and more deaths and disabilities, stroke has become a serious threat to human health
The OEA–soybean phosphatidylcholine (SPC) NPs could inhibit the inflammation of reperfusion to a very slight level and protect the neurons
Preparation of OEA–SPC Nanoparticles (OEA–SPC NPs) Different from other drug delivery systems, a key feature of the SPC-based nanoparticles is the preparation of drug-SPC complex via forming hydrogen bond between drug and SPC molecules, which would greatly improve the pharmaceutical properties of the drug
Summary
Leading to more and more deaths and disabilities, stroke has become a serious threat to human health. In addition to the high mortality, the high rate of long-term disability is the other reason which makes stroke a serious threat to human health [2]. The development of neuroprotective drugs has received considerable research interest and a number of promising neuroprotective agents have been identified in preclinical studies, no one can achieve success in clinical trials [8]. The reason for this are various: (1) the difference between
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
